Recently, Hikita et al reported that combining Sorafenib with ABT-737 would efficiently promote apoptosis in HCC cells which were relatively resistant to ABT-737, through the suppression of Mcl-1 by Sorafenib [33]. Here, MCL1 is linked to hepatocellular carcinoma.